Literature DB >> 24944785

Acute oxalate nephropathy induced by oral high-dose vitamin C alternative treatment.

Louis-Denis Poulin1, Julie Riopel2, Vincent Castonguay3, Fabrice Mac-Way1.   

Abstract

Entities:  

Year:  2014        PMID: 24944785      PMCID: PMC3970339          DOI: 10.1093/ckj/sfu013

Source DB:  PubMed          Journal:  Clin Kidney J        ISSN: 2048-8505


× No keyword cloud information.
A 59 year-old woman presented for abdominal pain, fatigue and decreased urine output. Eight months before she underwent a hysterectomy with bilateral salpingo-oophorectomy for a uterine leiomyosarcoma but was diagnosed 6 months later with local recurrence. She refused radiotherapy and palliative chemotherapy but rather preferred alternative treatment with oral high-dose vitamin C. Acute renal failure (ARF) was diagnosed (creatinine 166 versus 48 µmol/L 2 months before) and urinalysis revealed abundant calcium oxalate. Abdominal scan did not reveal renal obstruction. Renal biopsy showed extensive tubular calcium oxalate crystal deposition with some degree of acute tubular injury and mild interstitial inflammation with eosinophils (Figures 1 and 2). She denied any ethylene glycol ingestion and she was not known for bypass surgery or malabsorption. Hemodialysis treatments were initiated to increase creatinine and for hypervolemia but unfortunately, her condition slowly deteriorated. After 3 weeks of hemodialysis, the patient's renal function has not recovered and she was finally transferred to palliative care unit. Oxalate nephropathy is mostly seen with ethylene glycol intoxication, malabsorption or in primary hyperoxaluria. Vitamin C is metabolized into oxalate and can induce ARF by precipitation of calcium oxalate in renal tubules when excessive dose is taken. The patient reported that she was taking over 4 g of vitamin C daily during 30 consecutive days. Our case combined to recently published papers [1-3] underline the importance for clinicians to increase their awareness about this potential but easily preventable complication in patients taking high-dose vitamin C as alternative treatment.
Fig. 1.

Intra-tubular deposition of calcium oxalate crystals (white arrows) and acute tubular injury in adjacent tubules. H&E ×20.

Fig. 2.

Birefringent calcium oxalate crystals under polarized light. H&E ×20.

Intra-tubular deposition of calcium oxalate crystals (white arrows) and acute tubular injury in adjacent tubules. H&E ×20. Birefringent calcium oxalate crystals under polarized light. H&E ×20.
  3 in total

1.  Oxalate nephropathy and intravenous vitamin C.

Authors:  L Nicholas Cossey; Fahim Rahim; Christopher P Larsen
Journal:  Am J Kidney Dis       Date:  2013-03-30       Impact factor: 8.860

2.  Vitamin C-induced oxalate nephropathy.

Authors:  Jorge Lamarche; Reji Nair; Alfredo Peguero; Craig Courville
Journal:  Int J Nephrol       Date:  2011-03-16

3.  Vitamin C-induced oxalate nephropathy: a case report.

Authors:  Harmeet Gurm; Mohamed Ali Sheta; Noel Nivera; Allan Tunkel
Journal:  J Community Hosp Intern Med Perspect       Date:  2012-07-16
  3 in total
  4 in total

1.  No Reported Renal Stones with Intravenous Vitamin C Administration: A Prospective Case Series Study.

Authors:  Melissa Prier; Anitra C Carr; Nicola Baillie
Journal:  Antioxidants (Basel)       Date:  2018-05-21

2.  N-acetylcysteine protects against star fruit-induced acute kidney injury.

Authors:  Maria Heloisa Massola Shimizu; Pedro Henrique França Gois; Rildo Aparecido Volpini; Daniele Canale; Weverton Machado Luchi; Leila Froeder; Ita Pfeferman Heilberg; Antonio Carlos Seguro
Journal:  Ren Fail       Date:  2016-11-15       Impact factor: 2.606

3.  Secondary Oxalate Nephropathy: A Systematic Review.

Authors:  Nuttha Lumlertgul; Monchai Siribamrungwong; Bertrand L Jaber; Paweena Susantitaphong
Journal:  Kidney Int Rep       Date:  2018-07-29

4.  Oxalate nephropathy: a review.

Authors:  Jordan L Rosenstock; Tatyana M J Joab; Maria V DeVita; Yihe Yang; Purva D Sharma; Vanesa Bijol
Journal:  Clin Kidney J       Date:  2021-08-12
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.